Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARV-806

Small molecule (PROTAC degrader) · Degrader of KRAS G12D (KRAS) · developed by Arvinas

Phase 1/2 Most advanced trial
ARVN Developer
1 Registered trials

What is ARV-806?

ARV-806 is a PROTAC-based degrader that targets KRAS G12D mutated protein through a ternary complex mechanism involving E3 ubiquitin ligase, leading to proteasome-mediated degradation of KRAS G12D. It is being studied in advanced solid cancers with KRAS G12D mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule (PROTAC degrader)
Targets
KRAS G12D (KRAS), E3 ubiquitin ligase (binding partner it blocks)
Mechanism
Degrader of KRAS G12D (KRAS)
Pathways
proteasome-mediated degradation, KRAS signaling, cell survival pathways
Therapy area
Oncology
Developer
Arvinas Inc. (ARVN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07023731 Phase 1/2 KRAS G12D Mutation Active not recruiting ARVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid CancerKRAS G12D Mutation

Other drugs acting on KRAS

Sotorasib FDA approved AN9025 Phase 1 Calderasib Phase 3 Elironrasib Phase 1/2 ERAS-0015 Phase 1 Olomorasib Phase 3 Zoldonrasib Phase 1/2

More from Arvinas

ARV-6723 Phase 1/2 Bavdegalutamide Phase 1/2 Zaloblideg Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ARVN page.

Follow ARVN, the company behind ARV-806

See ARVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARVN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.